| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | David A. Isenberg | Q42326409 |
| Michael R Ehrenstein | Q60017325 | ||
| P2093 | author name string | Rahman A | |
| Manson JJ | |||
| P433 | issue | 7 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 1052-1056 | |
| P577 | publication date | 2007-05-11 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | Fifty years of anti-ds DNA antibodies: are we approaching journey's end? | |
| P478 | volume | 46 |
| Q41882936 | 4. Kidneys and Autoimmune Disease |
| Q37311326 | A novel DNA/histone H4 peptide complex detects autoantibodies in systemic lupus erythematosus sera |
| Q38114501 | Aberrant B cell selection and activation in systemic lupus erythematosus |
| Q52603256 | Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests. |
| Q35931319 | Anti-DNA autoantibodies initiate experimental lupus nephritis by binding directly to the glomerular basement membrane in mice |
| Q26776493 | Anti-dsDNA Antibodies are one of the many autoantibodies in systemic lupus erythematosus |
| Q36954627 | Anti-dsDNA antibodies bind to TLR4 and activate NLRP3 inflammasome in lupus monocytes/macrophages |
| Q35620345 | Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus |
| Q46941538 | Assessment of the translational value of mouse lupus models using clinically relevant biomarkers |
| Q37202064 | Association between IgG4 Autoantibody and Complement Abnormalities in Systemic Lupus Erythematosus. |
| Q96135115 | Association between antinuclear antibodies (ANA) patterns and extractable nuclear antigens (ENA) in HEp-2 cells in patients with autoimmune diseases in Riyadh, Saudi Arabia |
| Q36134326 | Association between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients with Systemic Lupus Erythematosus |
| Q37256378 | Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register |
| Q50972538 | Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease. |
| Q38023852 | Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown. |
| Q51724948 | Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE. |
| Q92057326 | Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial |
| Q33398064 | BioPlex 2200 multiplexed system: simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus |
| Q37994309 | Biomarkers for systemic lupus erythematosus |
| Q51016561 | CCR5Δ32 (rs333) polymorphism is associated with the susceptibility to systemic lupus erythematosus in female Brazilian patients. |
| Q46459006 | Cell-bound complement activation products in SLE. |
| Q38237868 | Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus |
| Q44862702 | Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE. |
| Q54144851 | Circulating hsa-miR-30e-5p, hsa-miR-92a-3p, and hsa-miR-223-3p may be novel biomarkers in systemic lupus erythematosus. |
| Q27001690 | Clinical perspectives on lupus genetics: advances and opportunities |
| Q35625532 | Comparison and evaluation of different methodologies and tests for detection of anti-dsDNA antibodies on 889 Slovenian patients' and blood donors' sera |
| Q37400362 | Concomitance of IgM and IgG anti-dsDNA Antibodies Does Not Appear to Associate to Active Lupus Nephritis |
| Q26782454 | Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus |
| Q36318958 | DNA-Containing Immunocomplexes Promote Inflammasome Assembly and Release of Pyrogenic Cytokines by CD14+ CD16+ CD64high CD32low Inflammatory Monocytes from Malaria Patients. |
| Q30251723 | DNA-damaging autoantibodies and cancer: the lupus butterfly theory |
| Q28546765 | Demethylzeylasteral (T-96) Treatment Ameliorates Mice Lupus Nephritis Accompanied by Inhibiting Activation of NF-κB Pathway |
| Q37353862 | Detecting shared pathogenesis from the shared genetics of immune-related diseases |
| Q48204990 | Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB. |
| Q37349227 | Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing |
| Q49966463 | Diagnostic and prognostic tests in systemic lupus erythematosus. |
| Q29417056 | Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production |
| Q41773764 | Differential immunoglobulin class-mediated responses to components of the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease |
| Q42144559 | ER Stress Proteins in Autoimmune and Inflammatory Diseases |
| Q30832522 | Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). |
| Q37673346 | Elevated expression of TIGIT on CD3+CD4+ T cells correlates with disease activity in systemic lupus erythematosus |
| Q36267460 | Establishing a reference interval for serum anti-dsDNA antibody: A large Chinese Han population-based multi-center study |
| Q42410966 | Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes |
| Q39389089 | Evaluation of the reactivity of sera from patients with systemic lupus erythematosus against the human MCP1. |
| Q35698898 | Genome-Wide Assessment of Differential DNA Methylation Associated with Autoantibody Production in Systemic Lupus Erythematosus |
| Q42601725 | High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q60046064 | Human Chorionic Gonadotropin Influences Systemic Autoimmune Responses |
| Q36477458 | Improved monitoring of clinical response in Systemic Lupus Erythematosus by longitudinal trend in soluble vascular cell adhesion molecule-1. |
| Q46252278 | Increased lipid and protein oxidation and lowered anti-oxidant defenses in systemic lupus erythematosus are associated with severity of illness, autoimmunity, increased adhesion molecules, and Th1 and Th17 immune shift. |
| Q33599086 | Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus |
| Q34638296 | Lupus: an overview of the disease and management options |
| Q26781272 | Mechanisms of Kidney Injury in Lupus Nephritis - the Role of Anti-dsDNA Antibodies |
| Q37221965 | Mediators of inflammation and their effect on resident renal cells: implications in lupus nephritis |
| Q34149941 | Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures |
| Q38767584 | Molecular and Immunological Basis of Tubulo-Interstitial Injury in Lupus Nephritis: a Comprehensive Review. |
| Q38099772 | Neutrophil extracellular chromatin traps connect innate immune response to autoimmunity |
| Q58134740 | Neutrophil to Lymphocyte Ratio and Mean Platelet Volume as Inflammatory Indicators in Systemic Lupus Erythematosus Nephritis |
| Q40173384 | Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation |
| Q44520690 | Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period |
| Q58134046 | Pathogenic effect of a cell-penetrating anti-dsDNA autoantibody through p38 signaling pathway and pro-inflammatory cytokine stimulation in mesangial cells |
| Q36966870 | Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus |
| Q92462298 | Periodontitis is associated with disease severity and anti-double stranded DNA antibody and interferon-gamma levels in patients with systemic lupus erythematosus |
| Q34709085 | Plasma DNA aberrations in systemic lupus erythematosus revealed by genomic and methylomic sequencing |
| Q34979215 | Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus |
| Q40610167 | Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins |
| Q91282440 | Precision medicine in lupus nephritis: can biomarkers get us there? |
| Q91933384 | Pregnancy and lactation interfere with the response of autoimmunity to modulation of gut microbiota |
| Q34339372 | Production of IgG autoantibody requires expression of activation-induced deaminase in early-developing B cells in a mouse model of SLE. |
| Q37638411 | Prolactin, systemic lupus erythematosus, and autoreactive B cells: lessons learnt from murine models |
| Q33806541 | Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis. |
| Q37186311 | Renal interstitial cells, proteinuria and progression of lupus nephritis: new frontiers for old factors |
| Q36186103 | Reno-protective effect and mechanism study of Huang Lian Jie Du Decoction on lupus nephritis MRL/lpr mice |
| Q27023280 | Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects |
| Q37328887 | Serum IL-18 as biomarker in predicting long-term renal outcome among pediatric-onset systemic lupus erythematosus patients. |
| Q44439756 | Simultaneous positivity for anti-DNA, anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis |
| Q35625811 | Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort. |
| Q89119530 | TACI deletion protects against progressive murine lupus nephritis induced by BAFF overexpression |
| Q28085243 | The Role of Anti-DNA Antibodies in the Development of Lupus Nephritis: A Complementary, or Alternative, Viewpoint? |
| Q38512653 | The anti-DNA antibody: origin and impact, dogmas and controversies |
| Q36850723 | The constant region contributes to the antigenic specificity and renal pathogenicity of murine anti-DNA antibodies |
| Q37681930 | The degree of CD4+ T cell autoreactivity determines cellular pathways underlying inflammatory arthritis |
| Q36040303 | The many faces of type I interferon in systemic lupus erythematosus |
| Q38206945 | The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved |
| Q37308042 | The search for lupus biomarkers |
| Q26786973 | To Extinguish the Fire from Outside the Cell or to Shutdown the Gas Valve Inside? Novel Trends in Anti-Inflammatory Therapies |
| Q41228881 | Translating epigenetics into clinic: focus on lupus |
| Q47684687 | Vascular endothelial growth factor as a prognostic marker of lupus nephritis |
| Q37236049 | Why can't we find a new treatment for SLE? |
Search more.